<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090621</url>
  </required_header>
  <id_info>
    <org_study_id>FEC-TH</org_study_id>
    <secondary_id>2012-000633-39</secondary_id>
    <nct_id>NCT02090621</nct_id>
  </id_info>
  <brief_title>Extracorporeal Photopheresis After Liver Transplant</brief_title>
  <official_title>Extracorporeal Photopheresis After Liver Transplant. Phase II Clinical Trial on Safety and Efficacy in Patients With Progressive Withdrawal of Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of photopheresis for prophylaxis of&#xD;
      allograft rejection in patients who are being withdrawal immunosuppression after liver&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The photopheresis (ECP) is a therapeutic approach based on the biological effect of&#xD;
      ultraviolet light A on mononuclear cells collected by apheresis, and reinfused into the&#xD;
      patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events associated with the procedure</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Non Serious Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Allograft Rejection</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunosuppressant level</measure>
    <time_frame>12 months</time_frame>
    <description>CyA, tacrolimus levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function test</measure>
    <time_frame>12 months</time_frame>
    <description>Total protein, albumin, bilirubin, GOT, GPT, alkaline phosphatase, gamma- GT, Quick index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function test</measure>
    <time_frame>12 months</time_frame>
    <description>Creatinine, urea, glomerular filtration rate (MDRD), creatinine clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological Parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Basic hematological parameters:&#xD;
Hemoglobin, hematocrit, platelets and leukocytes.&#xD;
Metabolic parameters:&#xD;
Glucose, uric acid, triglycerides, cholesterol, HDL and LDL cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Study of the evolution of subpopulations of blood mononuclear cells peripheral (T cells, B cells and dendritic cells) During removal of the SI measured by flow cytometry of different lymphocyte populations and are expressed as% and / or item # cells / L blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Extracorporeal Photopheresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extracorporeal Photopheresis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extracorporeal photopheresis</intervention_name>
    <description>Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.</description>
    <arm_group_label>Extracorporeal Photopheresis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver transplantation 2 years ago&#xD;
&#xD;
          -  &gt;18 years&#xD;
&#xD;
          -  Treatment with immunosuppression (Cyclosporine or tacrolimus)&#xD;
&#xD;
          -  Normal hepatic function during last year&#xD;
&#xD;
          -  No acute or chronic rejection&#xD;
&#xD;
          -  to have some secondary effect because of immunosuppressors&#xD;
&#xD;
          -  Previous disease: alcoholic liver cirrhosis with or without hepatocarcinoma, metabolic&#xD;
             disease, amyloid polyneuropathy, hepatitis,cryptogenic cirrhosis and non autoimmune&#xD;
             causes&#xD;
&#xD;
          -  Signing consent informed form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Additional liver Transplantation&#xD;
&#xD;
          -  hypersensitivity to methoxsalen&#xD;
&#xD;
          -  Patients with melanoma ,cutaneous carcinoma&#xD;
&#xD;
          -  Patients with aphakia&#xD;
&#xD;
          -  Patients treated with oxsoralen&#xD;
&#xD;
          -  Pregnant women, lactating women or fertile adults that they don´t use a effective&#xD;
             anticonception method&#xD;
&#xD;
          -  Involved in other assay.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Antonio Pons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínco Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jose Antonio Pons, MD</name>
      <address>
        <city>Murcia</city>
        <state>El Palmar</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Pons JA, Yélamos J, Ramírez P, Oliver-Bonet M, Sánchez A, Rodríguez-Gago M, Navarro J, Bermejo J, Robles R, Parrilla P. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation. 2003 Apr 15;75(7):1045-7.</citation>
    <PMID>12698096</PMID>
  </reference>
  <reference>
    <citation>Pons JA, Ramírez P, Revilla-Nuin B, Pascual D, Baroja-Mazo A, Robles R, Sanchez-Bueno F, Martinez L, Parrilla P. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant. 2009 Jun-Jul;23(3):329-36. doi: 10.1111/j.1399-0012.2008.00944.x. Epub 2009 Feb 5.</citation>
    <PMID>19210687</PMID>
  </reference>
  <reference>
    <citation>Pons JA, Revilla-Nuin B, Baroja-Mazo A, Ramírez P, Martínez-Alarcón L, Sánchez-Bueno F, Robles R, Rios A, Aparicio P, Parrilla P. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation. 2008 Nov 27;86(10):1370-8. doi: 10.1097/TP.0b013e318188d3e6.</citation>
    <PMID>19034005</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>September 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver</keyword>
  <keyword>transplantation</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>photopheresis</keyword>
  <keyword>extracorporeal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

